Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma
Authors:
- S. MillerSMS. Miller
- H. A. RogersHRH. A. Rogers
- P. LyonPLP. Lyon
- V. RandVRV. Rand
- M. Adamowicz-BriceMAM. Adamowicz-Brice
- S. C. CliffordSCS. C. Clifford
- J. T. HaydenJHJ. T. Hayden
- S. DyerSDS. Dyer
- S. PfisterSPS. Pfister
- A. KorshunovA. Korshunov
- M.-A. BrundlerMBM.-A. Brundler
- J. LoweJLJ. Lowe
Open Access
- 28 July 2011
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (8) , 866-879
Abstract
Central nervous system primitive neuroectodermal tumor (CNS PNET) and pineoblastoma are highly malignant embryonal brain tumors with poor prognoses. Current therapies are based on the treatment of pediatric medulloblastoma, even though these tumors are distinct at both the anatomical and molecular level. CNS PNET and pineoblastoma have a worse clinical outcome than medulloblastoma; thus, improved therapies based on an understanding of the underlying biology of CNS PNET and pineoblastoma are needed. To this end, we characterized the genomic alterations of 36 pediatric CNS PNETs and 8 pineoblastomas using Affymetrix single nucleotide polymorphism arrays. Overall, the majority of CNS PNETs contained a greater degree of genomic imbalance than pineoblastomas, with gain of 19p (8 [27.6%] of 29), 2p (7 [24.1%] of 29), and 1q (6 [20.7%] of 29) common events in primary CNS PNETs. Novel gene copy number alterations were identified and corroborated by Genomic Identification of Significant Targets In Cancer (GISTIC) analysis: gain of PCDHGA3, 5q31.3 in 62.1% of primary CNS PNETs and all primary pineoblastomas and FAM129A, 1q25 in 55.2% of primary CNS PNETs and 50% of primary pineoblastomas. Comparison of our GISTIC data with publically available data for medulloblastoma confirmed these CNS PNET-specific copy number alterations. With use of the collection of 5 primary and recurrent CNS PNET pairs, we found that gain of 2p21 was maintained at relapse in 80% of cases. Novel gene copy number losses included OR4C12, 11p11.12 in 48.2% of primary CNS PNETs and 50% of primary pineoblastomas. Loss of CDKN2A/B (9p21.3) was identified in 14% of primary CNS PNETs and was significantly associated with older age among children (P = .05). CADPS, 3p14.2 was lost in 27.6% of primary CNS PNETs and was associated with poor prognosis (P = .043). This genome-wide analysis revealed the marked molecular heterogeneity of CNS PNETs and enabled the identification of novel genes and clinical associations potentially involved in the pathogenesis of these tumors.Keywords
This publication has 54 references indexed in Scilit:
- Subtypes of medulloblastoma have distinct developmental originsNature, 2010
- Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomasNeuro-Oncology, 2010
- Cross-species genomics matches driver mutations and cell compartments to model ependymomaNature, 2010
- Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain TumorsCancer Cell, 2009
- Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemiaCancer Genetics and Cytogenetics, 2009
- An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET)British Journal of Cancer, 2009
- High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A geneBMC Genomics, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- The International HapMap ProjectNature, 2003
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001